Press Releases

ALBUQUERQUE, N.M. – U.S. Representatives Teresa Leger Fernández (D-N.M.), Melanie Stansbury (D-N.M.), and Gabe Vasquez (D-N.M.), and U.S. Senators Ben Ray Luján and Martin Heinrich (D-N.M.) are announcing $3,068,909 from the U.S. Department of Health and Human Services (HHS) to Tribal communities to serve individuals with opioid use disorder and co-occurring substance use disorders by funding culturally specific and evidence-based treatment, including medication for the treatment of opioid use disorder (MOUD). These HHS Tribal Opioid Response Grants are being awarded through the Substance Abuse and Mental Health Services Administration (SAMHSA).

“For far too long, opioid addiction has ravaged our Tribal communities, and the need for culturally specific treatments is critical,” said Leger Fernández. “This funding will help provide life-saving treatment, tailored to the needs of Native communities, so that we can address the opioid crisis head-on. By combining evidence-based practices with the cultural knowledge of our Tribes, we can offer real hope and healing. I will continue to fight for more resources and support to make sure every New Mexican has access to the care they need to recover and thrive.” 

“Tackling the opioid crisis with the urgency it demands means expanding our approach. That includes everything from providing improved access to the lifesaving medication used to treat opioid use disorder to empowering local communities to develop treatment programs that are grounded in their distinct experiences and cultures. I’m proud to welcome over $3 million for Tribal communities to do exactly that," said Heinrich. “I won’t stop fighting to eliminate barriers to life saving medication and help New Mexicans get the care they need.” 

“Far too many across our Tribal lands have seen firsthand how the opioid epidemic has devastated our communities,” said Luján, a member of the Indian Affairs and Health, Education, Labor and Pensions Committees. “This $3+ million in federal funding will deliver critical treatments and medications to address opioid use disorder in our Tribal communities. Throughout my time in Congress, I have secured millions to expand opioid use disorder treatments, introduced bipartisan legislation to increase investments in substance misuse prevention, and called for an increase in funding in our nation’s response to the opioid use disorder epidemic. I am proud to welcome this funding alongside our Congressional delegation and will keep fighting to expand addiction treatment services and protect the health of our Tribal brothers and sisters.” 

“Culturally informed care is vital to addressing the opioid crisis in every community that is suffering,” said Stansbury. “This $3 million investment will help Tribal communities take care as they see fit, as they know what is best for their communities. I will continue to fight for more funding and tools to solve this crisis so New Mexicans can not only recover from addiction but thrive in life.” 

“New Mexico’s Tribes and Pueblos have long faced significant challenges in combating the opioid crisis. I’m proud to welcome these funds to provide critical resources to help address opioid addiction head-on,” said Vasquez. “Supporting culturally specific and evidence-based treatments ensures that we’re not only tackling the crisis but also providing Indian Country with the tools they need to better support recovery. I’m committed to securing more funding and resources to combat this crisis and save lives.” 

The N.M. Delegation has continuously worked to make opioid use disorder treatments more readily available.

This month, Heinrich introduced the Broadening Utilization of Proven and Effective Treatment for Recovery Act, or BUPE for Recovery Act, legislation to increase access to buprenorphine — a lifesaving drug used to treat opioid use disorder — by removing barriers providers and patients face when trying to access the medication. The BUPE for Recovery Act temporarily exempts buprenorphine from the U.S. Drug Enforcement Administration’s (DEA) Suspicious Orders Report System (SORS) requirements during the opioid public health emergency. SORS reporting requirements have led to an uncertainty among pharmacies and distributors to stock and dispense buprenorphine, which can prevent individuals suffering from opioid use disorder from receiving timely and effective treatment. This legislation will mitigate the treatment gap created by stringent SORS reporting requirements, reducing overdose deaths, saving lives, and improving public health outcomes. 

In the Fiscal Year 2025 (FY25) Commerce, Justice, Science, and Related Agencies (CJS)Appropriations Bill, Heinrich successfully included language directing the DEA to take further action to remove barriers to access for opioid use disorder medications such as buprenorphine. The inclusion of this language will assist local medical and mental health providers and make medications, including buprenorphine, more accessible to New Mexicans. 

Find an extensive list of Heinrich’s actions to tackle the fentanyl crisis and make opioid use disorder treatments more readily available here.